News

Johnson & Johnson Innovation Grant Aimed at Veteran Healthcare

A 2021 report by the U.S. Department of Health and Human Services found that Veterans are significantly more likely to develop multiple chronic health conditions in their lifetime like hypertension, arthritis, and cancer compared to non-Veterans. [1] To help treat wounded warriors and keep the military community healthy, we feel we must seek to identify and advance solutions with the potential to help address their medical needs.

To that end, Johnson & Johnson Innovation, together with Johnson & Johnson Office of Military and Veterans Affairs, is proud to continue the Veterans Lead QuickFire Challenge series. Innovators are invited to submit potentially ground-breaking ideas that aim to directly address the health care needs of the military community including cardiovascular disease [2], kidney disease [3], oncology [4], orthopedic and musculoskeletal disease [5], physical trauma management [6], respiratory health [7], and vision loss. [8]

The innovator(s) with the best idea, technology, or potential solution can receive grant funding from up to a total of $250,000, access to the Johnson & Johnson Innovation – JLABS ecosystem, and mentorship from experts across the Johnson & Johnson Family of Companies*.

* Subject to the execution of the necessary documentation and award agreement

 

Application Process

Potential solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Uniqueness of the idea
  • Potential impact on human health, specifically the military-connected community’s health
  • Feasibility of the idea
  • Thoroughness of approach
  • Identification of key resources and plan to further idea

The challenge is now accepting applications. The deadline to apply is September, 17 2021.

Recent News

10/26/2026

ATCC Selected by ARPA-H to Support Next-Generation BioStabilization Technologies

ATCC has been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an affiliate to provide independent verification and validation (IV&V) for its BioStabilization Systems (BoSS) program. Through this program, BoSS is taking the “200-degree leap,” from -196°C toward room temperature, to make life-saving cell therapies as easy to store and ship as …

10/26/2026

Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing treatments for serious inflammatory diseases, today announced that Celia Economides, the Company’s current Executive Vice President of Finance, is expected to be appointed Chief Financial Officer effective promptly after the Company’s reconvened 2026 Annual Meeting of Stockholders, if certain …

10/23/2026

PAK BioSolutions and iBET Advance Integrated Continuous AAV8 Purification

PAK BioSolutions today announced the publication of a peer-reviewed study on integrated, continuous purification of adeno-associated virus serotype 8 (AAV8) using the PAK PD™ Process Development Scale Continuous Purification System. Conducted in collaboration with iBET – Instituto de Biologia Experimental e Tecnológica, the study, “Streamlining AAV8 Purification with Cyclic Integrated Capture–Polishing Chromatography,” was published in …